文献速递浆细胞疾病

靶抗原与浆细胞表型是响应适应性达雷妥尤单抗治疗敏感性的关键因素

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
PubMed 文献 · Blood · 2026-01-01

该响应适应性临床试验对老年初诊多发性骨髓瘤患者给予达雷妥尤单抗单药治疗,2周期后达部分缓解者继续单药,否则加用来那度胺或硼替佐米。总缓解率97%,37%患者能继续单药;较高CD38表达、浆细胞基因表达编程及活化免疫肿瘤微环境与继续单药相关,而需加药者黏附、TNF信号、KRAS信号和B细胞程序表达增加且免疫微环境受抑。

要点

  • 2周期后达部分缓解者继续达雷妥尤单抗单药,否则加用来那度胺或硼替佐米
  • 总缓解率97%,37%患者能继续达雷妥尤单抗单药治疗
  • 较高CD38表达、浆细胞基因表达编程和活化免疫肿瘤微环境与继续单药相关

核心结论

  • 靶抗原表达、浆细胞表型和活化免疫肿瘤微环境是与CD38单克隆抗体治疗反应相关的关键特征。
  • 据作者所知,这是首项证明响应适应性达雷妥尤单抗治疗在脆弱初治多发性骨髓瘤患者中有效并描述单药敏感性关键生物标志物的研究。

研究设计与样本

  • 响应适应性临床试验,对老年初诊多发性骨髓瘤患者给予达雷妥尤单抗单药治疗。
  • 2周期后达部分缓解者继续达雷妥尤单抗,否则加用来那度胺或硼替佐米。
  • 试验注册号NCT04151667。

主要发现

  • 总缓解率97%,不良事件发生率低,37%患者能继续达雷妥尤单抗单药治疗。
  • 较高CD38表达、浆细胞基因表达编程和活化免疫肿瘤微环境与能继续达雷妥尤单抗单药治疗的患者相关。
  • 需加用来那度胺或硼替佐米者黏附、肿瘤坏死因子信号、KRAS信号和B细胞程序表达增加,且免疫肿瘤微环境受抑。
  • 仅2周期达雷妥尤单抗单药后即观察到富集新发耐药基因表达程序的亚克隆选择。
  • 复发时达雷妥尤单抗难治性骨髓瘤细胞表现为预先存在的小亚克隆扩增,其混合转录组程序含CD38表达降低的浆细胞表型并维持耐药程序。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this response-adapted clinic trial with daratumumab monotherapy for older patients with newly diagnosed multiple myeloma (MM), we identified target antigen expression, a plasma cell phenotype, and an activated immune tumor microenvironment (iTME) as critical features associated with response to CD38 monoclonal antibody therapy. Here, patients achieving a partial response after 2 cycles continued daratumumab, otherwise lenalidomide or bortezomib was added. This strategy resulted in an overall response rate of 97% and low rates of adverse events, with 37% of patients able to continue daratumumab monotherapy. Importantly, we found that higher CD38 expression, plasma cell gene expression programming, and an activated iTME were associated with patients who were able to continue daratumumab therapy alone. In contrast, patients requiring the addition of lenalidomide or bortezomib had increased expression of adhesion, tumor necrosis factor signaling, KRAS signaling, and B-cell programs, as well as an immunosuppressed iTME. Tracking of clonal dynamics illustrated the selection of subclones enriched for de novo resistance gene expression programs after only 2 cycles of daratumumab monotherapy. Upon relapse, daratumumab refractory MM cells were characterized by the expansion of preexisting minor subclones with mixed transcriptomic programs containing the plasma cell phenotype with decreased CD38 expression and maintenance of resistance programs, suggesting development of acquired resistance involves an uncoupling of transcriptional programs present in therapy-naïve tumors. To our knowledge, this is the first study to demonstrate the effectiveness of response-adapted daratumumab treatment and describe critical biomarkers of single-agent daratumumab sensitivity in vulnerable patients with therapy-naïve MM. This trial was registered at www.ClinicalTrials.gov as #NCT04151667.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Meads MB, Zhao X, Noyes D, et al. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2026. PMID: 40983035. doi:10.1182/blood.2025029921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。